Skip to content
  • Tuesday, 27 October 2026
  • 4:55 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Gilead Sciences Finalizes $5 Billion Acquisition of Tubulis, Bolstering Oncology Pipeline with Advanced ADC Technology
Pharmaceutical R&D

Gilead Sciences Finalizes $5 Billion Acquisition of Tubulis, Bolstering Oncology Pipeline with Advanced ADC Technology

Teuku Ryan May 23, 2026 0

Gilead Sciences has officially completed its acquisition of Tubulis, a prominent German biotechnology firm specializing in the development of next-generation…

Read More
Pharmaceutical R&D

Gilead Acquires Antibody-Drug Conjugate Pioneer Tubulis for Up to $5 Billion, Bolstering Oncology Pipeline

Teuku Ryan Apr 7, 2026 0

Sixteen months after forging a strategic collaboration, Gilead Sciences has announced its definitive agreement to acquire German biotechnology firm Tubulis,…

Read More
Sai Life Sciences’ Biotech Pitch Day 2026 Spotlights Pioneering Early-Stage Biotech Innovations Addressing Critical Unmet Medical NeedsGravitational Waves from Colliding Black Holes May Reveal the Secret of Dark MatterESMO 2026 Oral Cell Cycle Inhibitors Place Cyclin E1 as New Target in Oncology and Precision MedicineA novel bacteriophage isolated from slaughterhouse wastewater and poultry farm effluent could be the key to protecting against Salmonella poisoning.
The Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactEliquis Loss of Exclusivity: A Pharmaceutical Patent Cliff of Historic ProportionsMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric Growth
Merck and Moderna’s cancer vaccine is customized for each patient’s tumorAn Unbiased Look at Google Gemini Omni: Features, Costs, and Market ComparisonESMO 2026: Sacituzumab Tirumotecan Sets New Survival Benchmark in Recurrent Endometrial CancerLight-Driven Magnetism Breakthrough Promises Ultrafast, High-Density Digital Data Storage
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Merck and Moderna’s cancer vaccine is customized for each patient’s tumor
Lana Keisha Oct 27, 2026
Data Science & Bioinformatics
An Unbiased Look at Google Gemini Omni: Features, Costs, and Market Comparison
Evan Lee Salim Oct 27, 2026
Pharmaceutical R&D
ESMO 2026: Sacituzumab Tirumotecan Sets New Survival Benchmark in Recurrent Endometrial Cancer
Teuku Ryan Oct 27, 2026
Advanced Materials Science
Light-Driven Magnetism Breakthrough Promises Ultrafast, High-Density Digital Data Storage
Nila Kartika Wati Oct 27, 2026

Copyright © 2026 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ